April 29, 2024: We strongly support today’s FDA’s decision to regulate lab-developed tests. Unfortunately, FDA’s final rules has compromised on the critical issue of grandfathering thousands of tests on the already on the market.
Read More »On Medical Treatments & Products
NCHR Comment on Labeling and Advertising of Beverages with Alcohol Content
April 4, 2024: NCHR advocates for mandatory labeling of alcohol beverages that includes portion size information about alcohol content, calories, allergens, and other ingredients. We explain why voluntary standards are inadequate and that consumers need and deserve the information that would enable them to make safe and healthy decisions.
Read More »Joint Comments to the Consumer Product Safety Commission on the Notice of Proposed Rulemaking: “Safety Standard for Infant Support Cushions”
March 18, 2024: NCHR was one of 6 Consumer Safety groups submitting joint comments to the Consumer Product Safety Commission (CPSC) for its Proposed Rule for Safety Standards for Infant Support Cushions
Read More »NCHR Comment on Classification of Certain Wound Dressings
NCHR supports the proposed FDA rule, which aims to reclassify wound dressings and liquid wound washes containing antimicrobials based on their level of antimicrobial resistance (AMR), with higher-risk products categorized as Class III. This change is crucial for mitigating the public health threat posed by AMR, ensuring the appropriate use of these medical devices, and ultimately improving patient outcomes.
Read More »Statement of Dr. Diana Zuckerman on Behalf of the National Center for Health Research FDA Advisory Committee Meeting on AMX0035 for ALS
September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving this drug would undermine other ALS clinical trials that are underway.
Read More »